United States Ventricular Assist Devices Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Global Ventricular Assist Devices Market is expected to reach at a CAGR of 10% during the forecast period 2024-2031

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ventricular-assist-devices-market?sb

Key Development:

United States: Recent Industry Developments

✅ In March 2026, Abbott announced continued expansion of its HeartMate 3 ventricular assist device clinical research program in the United States to evaluate long-term outcomes in advanced heart failure patients. The study focuses on improving survival rates and reducing complications through advanced pump technology. It supports wider adoption of mechanical circulatory support in critical cardiac care.

✅ In February 2026, Medtronic invested in next-generation mechanical circulatory support technologies including compact ventricular assist devices designed for minimally invasive implantation. The investment aims to enhance patient mobility and long-term device durability. It strengthens U.S. innovation in advanced heart failure treatment solutions.

✅ In January 2026, Abiomed, a Johnson & Johnson company, launched an upgraded Impella heart pump platform for high-risk cardiac procedures in the United States. The system provides improved hemodynamic support during complex interventions. It expands the use of temporary ventricular assist devices in critical care settings.

✅ In December 2025, the U.S. FDA granted approval for a clinical trial evaluating a fully implantable ventricular assist device with wireless energy transfer technology. The device is designed to eliminate external driveline cables and reduce infection risk. It represents a major step toward next-generation long-term cardiac support systems.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ventricular-assist-devices-market

Japan: Recent Industry Developments

✅ In March 2026, Terumo Corporation announced development of a next-generation ventricular assist device designed for long-term use in patients with severe heart failure. The system focuses on compact size, improved durability, and reduced thrombosis risk. It supports Japan's efforts to advance mechanical circulatory support technologies.

✅ In February 2026, Evaheart Medical initiated new clinical evaluations of its implantable ventricular assist device to improve performance and patient safety in long-term therapy. The study focuses on optimizing pump efficiency and reducing complications. It strengthens Japan's position in advanced cardiac assist technologies.

✅ In January 2026, Nipro Corporation invested in research and development for artificial heart and ventricular assist device components including advanced blood pump systems. The initiative focuses on improving reliability and biocompatibility. It aims to support growing demand for cardiac support devices in Japan.

✅ In December 2025, Sun Medical Technology Research Corp. announced progress in developing compact ventricular assist systems for bridge-to-transplant therapy. The technology is designed to support patients waiting for heart transplantation. It contributes to Japan's innovation in life-support medical devices.

Key Players:

=> Abbott Laboratories, Abiomed Inc, Berlin Heart GmbH, Medtronic Plc, Jarvik Heart, Inc., EVAHEART, INC., Cirtec, CorWave SA, Calon Cardio-Technology Ltd, and Teleflex Incorporated.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ventricular-assist-devices-market?sb

Key Segments:

By Product Type

Left Ventricular Assist Devices (LVADs) dominate with 50% share, driven by their widespread use in patients with severe left ventricular heart failure, which is the most common form of advanced heart disease. Right Ventricular Assist Devices (RVADs) account for 20%, supported by their use in patients with right heart failure, often in combination with other cardiac support therapies. Biventricular Assist Devices (BiVADs) hold 30%, fueled by increasing cases of advanced heart failure requiring support for both ventricles.

By Design

Implantable Ventricular Assist Devices lead with 70% share, driven by their long-term use in patients waiting for heart transplant or requiring permanent cardiac support. These devices provide better mobility and improved quality of life. Transcutaneous Ventricular Assist Devices account for 30%, supported by their use in short-term treatment and emergency cardiac support where external connections are required.

By Application

Bridge to Transplant Therapy dominates with 35% share, driven by increasing number of patients waiting for heart transplants and the need for temporary cardiac support. Destination Therapy accounts for 25%, supported by patients who are not eligible for transplant but require long-term heart assistance. Bridge to Recovery Therapy holds 20%, fueled by cases where heart function is expected to improve after temporary support. Bridge to Candidacy Therapy represents 20%, used to stabilize patients until they become eligible for transplant or other treatments.

By End-User

Hospitals dominate with 65% share, due to the need for advanced surgical facilities, intensive care units, and specialized cardiac treatment centers. Specialty Clinics account for 15%, supported by increasing number of cardiac care centers providing follow-up and monitoring services. Ambulatory Surgical Centers hold 10%, driven by growth in minimally invasive cardiac procedures. Others represent 10%, including research institutes and rehabilitation centers.

By Region

North America - 40% Share
North America leads with 40%, driven by high prevalence of heart failure, advanced healthcare infrastructure, and strong adoption of ventricular assist devices in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by increasing cardiac surgeries, strong reimbursement policies, and growing awareness of advanced heart failure treatments across Germany, the U.K., France, and Italy.

Asia Pacific - 22% Share
Asia Pacific accounts for 22%, fueled by improving cardiac care facilities, rising cardiovascular diseases, and growing healthcare investments in China, India, Japan, and South Korea.

Middle East & Africa - 7% Share
The Middle East & Africa represent 7%, driven by expanding healthcare infrastructure and increasing demand for advanced cardiac treatment.

Latin America - 6% Share
Latin America holds 6%, supported by gradual adoption of advanced medical devices and improving access to cardiac care in Brazil, Mexico, and Argentina.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.